First dual binder of microRNA-146a and monomeric tau: a novel approach for multitargeted therapeutics for neurodegenerative diseases. Academic Article uri icon

Overview

abstract

  • We report a new approach for the development of multitargeted therapeutics for Alzheimer's disease (AD) based on dual targeting of monomeric tau and biogenesis of microRNA-146a. Compound MG-1102 displayed a superior neuroprotective activity, in comparison to mono-targeted therapeutics, which validates the likelihood of the success of this approach in AD drug development.

publication date

  • August 20, 2020

Research

keywords

  • Alzheimer Disease
  • MicroRNAs
  • Neuroprotective Agents
  • tau Proteins

Identity

Scopus Document Identifier

  • 85089787708

Digital Object Identifier (DOI)

  • 10.1039/d0cc04249h

PubMed ID

  • 32699863

Additional Document Info

volume

  • 56

issue

  • 67